{"id":4019,"date":"2019-01-29T16:29:57","date_gmt":"2019-01-29T10:59:57","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=4019"},"modified":"2021-07-24T12:57:11","modified_gmt":"2021-07-24T07:27:11","slug":"notizia-88","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/notizia-88","title":{"rendered":"Biodesix collaborates with MRM; Avoiding flu with an antibody; Soliris clears trial"},"content":{"rendered":"\n<p class=\"has-background has-pale-cyan-blue-background-color\"><strong>Biodesix\ncollaborates with MRM for development of mass-spec proteomics<\/strong><\/p>\n\n\n\n<p><strong>Biodesix, the lung cancer diagnostic developer<\/strong> is collaborating with <strong>MRM Proteomics<\/strong> to authorize its <strong>iMALDI automated assay technology <\/strong>for quantifying <strong>proteins <\/strong>using <strong>mass spectrometry<\/strong>. It is done with the goal of enabling precision therapies. Under the agreement, Biodesix plans to use the technology to develop its blood-based <a href=\"https:\/\/www.delveinsight.com\/report-store\/non-small-cell-lung-cancer-market\">lung <\/a>tests that will focus on profiling the proteins and drug targets involved in the body\u2019s larger immune response to <strong>cancer <\/strong>instead of the genetic alterations that may drive the growth of tumours themselves.<\/p>\n\n\n\n<p class=\"has-background has-pale-cyan-blue-background-color\"><strong>Avoiding\nflu with an antibody and Tamiflu universal vaccine<\/strong><\/p>\n\n\n\n<p>Researchers at the <strong>National Institutes of Health\u2019s National Institute of Allergy and Infectious Diseases (NIAID)<\/strong> have found protection against the flu and it rests partly on FDA-approved remedy <strong>Tamiflu <\/strong>of <strong>Roche<\/strong>. The NIAID team tested an antibody that identifies a protein called <strong>hemagglutinin <\/strong>using mouse models of flu, which rests on the surface of the virus and spreads to healthy cells. Current flu vaccines work by recognizing the head of hemagglutinin and stopping its ability to transport the virus into cells. <\/p>\n\n\n\n<p class=\"has-background has-pale-cyan-blue-background-color\"><strong>Soliris\nof Alexion clears trial of <\/strong><strong>atypical hemolytic\nuremic syndrome<\/strong><strong><\/strong><\/p>\n\n\n\n<p><strong>Alexion Pharmaceuticals<\/strong>, an American pharmaceutical company best known for its development of <strong>Soliris<\/strong>, a drug used to treat the <strong>rare disorders atypical hemolytic uremic syndrome<\/strong> and paroxysmal nocturnal hemoglobinuria<strong>. <\/strong>The top-line data comes from a study of the complement C5 inhibitor in patients with atypical hemolytic uremic syndrome (<strong>aHUS<\/strong>). In the trial, Ultomiris (ravulizumab) met its targets of improving blood profile and <a href=\"https:\/\/www.delveinsight.com\/report-store\/acute-renal-failure-arf-acute-kidney-injury-market\">kidney <\/a>function, with more than half of patients with the ultrarare disease having a complete thrombotic microangiopathy (TMA) response. <\/p>\n","protected":false},"excerpt":{"rendered":"<p>Biodesix collaborates with MRM for development of mass-spec proteomics Biodesix, the lung cancer diagnostic developer is collaborating with MRM Proteomics to authorize its iMALDI automated assay technology for quantifying proteins using mass spectrometry. It is done with the goal of enabling precision therapies. Under the agreement, Biodesix plans to use the technology to develop its [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":3711,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[32],"tags":[2503,2028,2501,2491,524,1567],"industry":[17225],"therapeutic_areas":[17239,17228,17278],"class_list":["post-4019","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-notizia","tag-ahus","tag-alexion-pharmaceuticals","tag-atypical-hemolytic-uremic-syndrome","tag-biodesix","tag-roche","tag-soliris","industry-pharmaceutical","therapeutic_areas-gastroenterology","therapeutic_areas-oncology","therapeutic_areas-other-diseases"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v25.8 (Yoast SEO v25.8) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Biodesix collaborates with MRM; Avoiding flu with an antibody<\/title>\n<meta name=\"description\" content=\"Biodesix, the lung cancer diagnostic developer is collaborating with MRM Proteomics to authorize its iMALDI automated assay technology...\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/notizia-88\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Biodesix collaborates with MRM; Avoiding flu with an antibody\" \/>\n<meta property=\"og:description\" content=\"Biodesix, the lung cancer diagnostic developer is collaborating with MRM Proteomics to authorize its iMALDI automated assay technology...\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/notizia-88\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2019-01-29T10:59:57+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2021-07-24T07:27:11+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2018\/12\/04103829\/rs-pills-pharma-opiat.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1200\" \/>\n\t<meta property=\"og:image:height\" content=\"630\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"DelveInsight\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"DelveInsight\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Biodesix collaborates with MRM; Avoiding flu with an antibody","description":"Biodesix, the lung cancer diagnostic developer is collaborating with MRM Proteomics to authorize its iMALDI automated assay technology...","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/notizia-88","og_locale":"en_US","og_type":"article","og_title":"Biodesix collaborates with MRM; Avoiding flu with an antibody","og_description":"Biodesix, the lung cancer diagnostic developer is collaborating with MRM Proteomics to authorize its iMALDI automated assay technology...","og_url":"https:\/\/www.delveinsight.com\/blog\/notizia-88","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2019-01-29T10:59:57+00:00","article_modified_time":"2021-07-24T07:27:11+00:00","og_image":[{"width":1200,"height":630,"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2018\/12\/04103829\/rs-pills-pharma-opiat.jpg","type":"image\/jpeg"}],"author":"DelveInsight","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"DelveInsight","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/notizia-88","url":"https:\/\/www.delveinsight.com\/blog\/notizia-88","name":"Biodesix collaborates with MRM; Avoiding flu with an antibody","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/notizia-88#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/notizia-88#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2018\/12\/04103829\/rs-pills-pharma-opiat.jpg","datePublished":"2019-01-29T10:59:57+00:00","dateModified":"2021-07-24T07:27:11+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a"},"description":"Biodesix, the lung cancer diagnostic developer is collaborating with MRM Proteomics to authorize its iMALDI automated assay technology...","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/notizia-88"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/notizia-88#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2018\/12\/04103829\/rs-pills-pharma-opiat.jpg","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2018\/12\/04103829\/rs-pills-pharma-opiat.jpg","width":1200,"height":630,"caption":"Johnson & Johnson"},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a","name":"DelveInsight","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","caption":"DelveInsight"}}]}},"author_meta":{"display_name":"DelveInsight","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/gtadmin"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2018\/12\/04103829\/rs-pills-pharma-opiat-300x158.jpg","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">aHUS<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Alexion Pharmaceuticals<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">atypical hemolytic uremic syndrome<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Biodesix<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Roche<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Soliris<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">aHUS<\/span>","<span class=\"advgb-post-tax-term\">Alexion Pharmaceuticals<\/span>","<span class=\"advgb-post-tax-term\">atypical hemolytic uremic syndrome<\/span>","<span class=\"advgb-post-tax-term\">Biodesix<\/span>","<span class=\"advgb-post-tax-term\">Roche<\/span>","<span class=\"advgb-post-tax-term\">Soliris<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 7 years ago","modified":"Updated 5 years ago"},"absolute_dates":{"created":"Posted on Jan 29, 2019","modified":"Updated on Jul 24, 2021"},"absolute_dates_time":{"created":"Posted on Jan 29, 2019 4:29 pm","modified":"Updated on Jul 24, 2021 12:57 pm"},"featured_img_caption":"","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/4019","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=4019"}],"version-history":[{"count":0,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/4019\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/3711"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=4019"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=4019"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=4019"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=4019"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=4019"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}